지속형 약물전달 기술 및 서비스 시장 : 적합제형별, 원리별, 전략별, 전달 분자 유형별, 사용 재료 유형별, 주요 지역별 - 업계 동향과 세계 예측(- 2035년)

Long-Acting Drug Delivery Technologies and Services Market by Compatible Dosage Form, Principle, Strategy, Type of Molecule Delivered, Type of Material Used, and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,962,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,154,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,378,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 26,114,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 지속형 약물전달 기술 및 서비스 시장 규모는 2035년까지 예측 기간 동안 13.1%의 연평균 복합 성장률(CAGR)로 확대되어 현재 10억 6,000만 달러에서 2035년까지 46억 2,000만 달러로 성장할 것으로 예상됩니다.

지속형 약물 전달 시스템은 신경 질환, 감염, 폐 질환, 안과 질환, 오피오이드 사용 장애 등 다양한 적응증을 치료하기 위한 의약품의 지속적 전달에 광범위하게 사용되고 있습니다. 이러한 시스템은 펩타이드, 항체, 백신의 효과적인 투여와 효능을 향상시킬 수 있습니다. 또한, 이러한 새로운 전달 시스템은 일반적으로 투여하기 어려운 고분자를 장기간에 걸쳐 효과적으로 투여할 수 있습니다. 지속형 약물 전달 시스템이 환자의 복약 순응도와 복약 순응도를 개선할 수 있다는 점에서 업계는 개발 중인 지속형 약물의 임상적, 상업적 활용을 위해 많은 노력을 기울여 왔습니다. 그 결과,(수개월에서 수년에 걸쳐) 장기간 효과를 나타내는 약물이 개발되고 있습니다. 장기지속형 치료제의 적용은 환자뿐만 아니라 의료 시스템에도 혜택을 줄 수 있는 잠재력을 가지고 있습니다. 특히, 이러한 제제들은 중저소득 국가에 거주하는 여성들의 치료에 도움이 될 수 있으며, 병원 방문 횟수 및 관련 비용을 크게 줄일 수 있기 때문입니다.

또한, 복잡한 제형에 따른 제형 및 개발의 어려움으로 인해 장시간 지속형 약물 전달 분야의 전문성을 가진 이해관계자들의 신뢰도가 크게 증가하고 있습니다. 이는 궁극적으로 의약품 개발자들이 기존 치료법에서 발생하는 병목현상을 해결하고 전반적인 임상 결과를 개선하는 데 도움이 될 것으로 보입니다. 이 분야의 기술 발전과 지속형 약물에 대한 수요 증가에 힘입어 지속형 약물 전달 기술 및 서비스 시장은 향후 상당한 성장세를 보일 것으로 예상됩니다.

현재 100개 이상의 장시간 지속형 약물 전달 기술이 수많은 질병 적응증에 대한 장시간 지속형 약물을 개발하기 위해 전 세계 기업별로 제공되고 있습니다.

경쟁 우위를 확보하기 위해 업계 이해관계자들은 여러 치료 영역에서 사용할 수 있는 새로운 지속형 약물전달 기술의 혁신과 개발에 적극 나서고 있습니다. 현재 40개 이상의 서비스 제공업체가 장시간 지속형 약물 전달의 개발 및 제조 서비스를 광범위하게 제공합니다. 시장은 세분화되어 있으며, 다양한 제형의 장기지속형 약물 전달 시스템 개발 및 제조에 대한 전문성을 갖춘 기존 진입업체와 소규모 업체들이 모두 존재합니다.

세계의 지속형 약물 전달 기술 및 서비스 시장에 대해 조사했으며, 시장 개요와 함께 적합 제형별/원리별/전략별/전달 분자 유형별/사용 재료 유형별/주요 지역별 동향, 시장 진출 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 서문

제2장 주요 요약

제3장 서론

제4장 기술 상황

제5장 서비스 제공업체 상황

제6장 기술 경쟁력 분석

제7장 기업 경쟁력 분석

제8장 기업 개요

• 본 장의 개요
• Adare Pharma Solutions
• AMW
• Bostal Drug Delivery
• Creative Biolabs
• ForDoz Pharma
• InnoCore Pharmaceuticals
• Integral BioSystems
• LATITUDE Pharmaceuticals
• Navin Saxena Research and Technology Centre(NSRT)
• Samyang Biopharm

제9장 파트너십 및 협업

제10장 출판물 분석

제11장 특허 분석

제12장 보조금 분석

제13장 시장 예측과 기회 분석

• 본 장의 개요
• 주요 전제와 예측 조사 방법
• 2035년까지 세계의 지속형 약물전달 기술 시장
• 2035년까지 세계의 지속형 약물전달 서비스 시장

제14장 결론

제15장 인터뷰 기록

제16장 부록 1 : 표 형식 데이터

제17장 부록 2 : 기업 및 단체 리스트

LSH

영문 목차

영문목차

LONG-ACTING DRUG DELIVERY TECHNOLOGIES AND SERVICES MARKET: OVERVIEW

As per Roots Analysis, the global long-acting drug delivery technologies and services market is estimated to grow from USD 1.06 billion in the current year to USD 4.62 billion by 2035, at a CAGR of 13.1% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Principle

• Manipulation of drug release from delivery systems
• Manipulation of in vivo clearance

Strategy

• Chemical Modification
• Micro-encapsulation
• Long-Acting Hydrogels
• Long-Acting Implants
• Long-Acting Microneedles
• Multivesicular Liposomes
• Nanocrystal Suspensions
• Protein Fusion

Compatible Dosage Form

• Long-Acting Injectables
• Long-Acting Implantables
• Long-Acting Oral,
• Topical / Transdermal
• Vaginal
• Other Dosage Forms

Type of Molecule Delivered

• Small Molecules
• Biologics
• Other Molecules

Type of Material Used

• Polymer based
• Non-polymer based

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and North Africa

LONG-ACTING DRUG DELIVERY TECHNOLOGIES AND SERVICES MARKET: GROWTH AND TRENDS

Long-acting drug delivery systems are being widely adopted for sustained delivery of pharmaceutical drugs to treat a plethora of disease indications, including neurological diseases, infectious diseases, pulmonary diseases, ophthalmological diseases and opioid use disorders. These systems enable effective administration and improved efficacy of peptides, antibodies and vaccines. These novel delivery systems also enable the effective administration of macromolecules for a long-term effect, which are otherwise difficult to administer. Given the potential of long-acting drug delivery systems to improve patient compliance and adherence to medication, industry players have undertaken numerous initiatives to enable the clinical and commercial translation of long-acting drugs under development. This has led to the development of drugs that exhibit prolonged effects (for a few months or years). The application of long-acting therapeutics has the potential to benefit not only the patients but also the healthcare system. In particular, these formulations are beneficial to treat women living in low / middle income countries, as it will result in a substantial drop in the anticipated clinic visits and associated costs.

Further, owing to the formulation and developmental challenges associated with complex dosage forms, the reliability of stakeholders having expertise in the long-acting drug delivery field has grown significantly. This will eventually aid drug developers to address bottlenecks stemming from conventional treatment options and improve the overall clinical outcome. Driven by the technological advancements in the field and rising demand for long-acting drugs, the long-acting drug delivery technologies and services market is anticipated to witness notable growth in the foreseen future.

LONG-ACTING DRUG DELIVERY TECHNOLOGIES AND SERVICES MARKET: KEY INSIGHTS

The report delves into the current state of the long-acting drug delivery technologies and services market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. At present, more than 100 long-acting drug delivery technologies are being offered by companies across the globe in order to develop long-acting drugs for a myriad of disease indications.

2. Nearly 90% of the technologies are based on manipulation of drug release profile; majority of these technologies can support the development of long-acting injectables with dosing intervals of at least a month.

3. In pursuit of gaining a competitive edge, industry stakeholders are actively innovating and developing novel long-acting drug delivery technologies that can be utilized across multiple therapeutic areas.

4. The current service providers landscape features the presence of over 40 companies, offering a wide range of development and manufacturing services for the long-acting delivery of drugs.

5. The market is fragmented, featuring the presence of both established players and small firms that have the expertise to develop / manufacture long-acting drugs / delivery systems for various dosage forms.

6. The growing interest in this domain is clearly evident from the rise in partnership activity; in fact, more than 60 collaborations related to long-acting drug delivery were inked in the last three years.

7. ~575 scientific articles published recently signify the focused efforts being led by researchers to identify and develop novel long-acting technologies and therapeutic interventions.

8. Over 1,200 patents related to long-acting drug delivery have been filed / granted by various stakeholders in order to protect the intellectual property generated within this field.

9. 400+ grants have been awarded for the ongoing R&D efforts for long-acting drug delivery; University of North Carolina and John Hopkins University have emerged as the most popular recipient organizations.

10. The market opportunity associated with long-acting drug delivery technologies is anticipated to witness an annualized growth of nearly 13% over the next decade.

LONG-ACTING DRUG DELIVERY TECHNOLOGIES AND SERVICES MARKET: KEY SEGMENTS

Manipulation of Drug Release from Delivery Systems Occupy the Largest Share of the Long-Acting Drug Delivery Technologies and Services Market

Based on the principle, the market is segmented into manipulation of drug release from delivery systems and manipulation of in vivo clearance. At present, manipulation of drug release from delivery systems segment holds the maximum share of the long-acting drug delivery technologies and services market. This trend is unlikely to change in the near future.

Micro-Encapsulation is Likely to Dominate the Long-Acting Drug Delivery Technologies and Services Market During the Forecast Period

Based on the strategy, the market is segmented into chemical modification, micro-encapsulation, long-acting hydrogels, long acting implants, long acting microneedles, multivesicular liposomes, nanocrystal suspensions and protein fusion. Currently, micro-encapsulation holds the maximum share of the long-acting drug delivery technologies and services market. This trend is unlikely to change in the near future. Further, the long-acting drug delivery technologies and services market for long-acting microneedles is likely to grow at a relatively higher CAGR.

Long Acting Injectables Occupy the Largest Share of the Long-Acting Drug Delivery Technologies and Services Market

Based on the compatible dosage form, the market is segmented into long acting injectables, long acting implantable, long-acting orals, long acting topicals / transdermals and other dosage forms. At present, long-acting injectables captures the highest share of the long-acting drug delivery technologies and services market. It is worth highlighting that long-acting drug delivery technologies and services market for implantable is likely to grow at relatively higher CAGR.

Small Molecules are the Fastest Growing Segment of the Long-Acting Drug Delivery Technologies and Services Market During the Forecast Period

Based on the type of molecules delivered, the market is segmented into small molecules, biologics and other molecules. It is worth highlighting that, currently, small molecules hold a larger portion of the long-acting drug delivery technologies and services market. This trend is likely to remain the same in the coming decade.

Polymer based Materials are likely to Dominate the Long-Acting Drug Delivery Technologies and Services Market During the Forecast Period

Based on the type of material used, the market is segmented into polymer-based materials and non-polymer based materials. It is worth highlighting that majority of the current long-acting drug delivery technologies and services market is captured by the polymer-based materials.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, and Middle East and North Africa. The majority of the share is expected to be captured by players based in North America and Europe. It is worth highlighting that, over the years, the market in Europe is expected to grow at a higher CAGR.

Example Players in the Long-Acting Drug Delivery Technologies and Services Market

• Adare Pharma Solutions
• AMW
• Bostal Drug Delivery
• Creative Biolabs
• ForDoz Pharma
• Innocore Pharmaceuticals
• Integral BioSystems
• LATITUDE Pharmaceuticals
• Navin Saxena Research and Technology Centre (NSRT)
• Samyang Biopharm

LONG-ACTING DRUG DELIVERY TECHNOLOGIES AND SERVICES MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the long-acting drug delivery technologies and services market, focusing on key market segments, including [A] principle, [B] strategy, [C] compatible dosage form, [D] type of molecule delivered, [E] type of material used and [F] key geographical regions.
• Market Landscape 1: A comprehensive evaluation of long-acting drug delivery technologies, considering various parameters, such as [A] principle, [B] strategy, [C] type of material used, [D] compatible dosage form(s), [E] extended dosing interval(s), [F] type of molecule(s) delivered, [G] highest phase of development, [H] number of approved drugs and [I] therapeutic area(s). Additionally, the chapter includes information on various technology developers, along with analysis based on multiple parameters, such as their [K] year of establishment, [L] company size, [M] location of headquarters and [N] most active players (in terms of number of technologies developed).
• Market Landscape 2: A comprehensive evaluation of contract service providers engaged in the long-acting drug delivery technologies and services market, considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] location of facilities, [E] type of service provider(s), [F] scale of operation, [G] compatible dosage form(s), [H] service(s) offered and [I] type of molecule(s) supported.
• Technology Competitiveness Analysis: A comprehensive competitive analysis of long-acting drugs delivery technologies, examining factors, such as [A] developer power and [B] technology strength.
• Company Competitiveness Analysis: A comprehensive competitive analysis of long-acting drugs delivery service providers, examining factors, such as [A] company strength and [B] service strength.
• Company Profiles: In-depth profiles of key industry players offering technologies and offering services in the field of long-acting drugs delivery, focusing on [A] company overviews, [B] technology portfolio, [C] service portfolio, [D] recent developments and [E] an informed future outlook.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2018, covering acquisitions, manufacturing agreements, product development and commercialization agreements, service alliance, technology licensing agreements, and other relevant agreements.
• Publication Analysis: A detailed analysis of over 570 peer-reviewed, scientific articles focused on research related to long acting drugs delivery, based on several relevant parameters, such as [A] year of publication, [B] type of publication, [C] popular keywords, [D] top journals, [E] top publishers, [F] top copyright holders and [G] key funding institutes (in terms of number of articles published).
• Patent Analysis: Detailed analysis of various patents filed / granted related to long-acting drug delivery based on [A] publication year, [B] geographical region, [C] CPC symbols, [D] leading players (in terms of number of patents filled / granted) and [E] type of organization. It also includes a patent benchmarking analysis and a detailed valuation analysis.
• Grant Analysis: A comprehensive evaluation of various grants that have been awarded to research institutes engaged in conducting research related to long-acting drug delivery, since 2018, based on various important parameters, such as [A] year of grant award, [B] amount awarded, [C] support period, [D] type of funding institute center, [E] type of grant application, [F] purpose of grant award, [G] activity code, [H] NIH spending category, [I] study section involved, [J] popular NIH departments (in terms of number of grants), [K] type of recipient organization, [L] prominent program officers (in terms of number of grants) and [M] popular recipient organizations (in terms of number of grants and amount awarded).

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Key Market Insights
• 1.3. Scope of the Report
• 1.4. Research Methodology
• 1.5. Frequently Asked Questions
• 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Overview of Long-Acting Drug Delivery
  • 3.2.1. Types of Long-Acting Drug Delivery Systems
• 3.3. Long-Acting Drug Delivery Technologies
  • 3.3.1. Underlying Principle
  • 3.3.2. Associated Strategies
• 3.4. Concluding Remarks

4. TECHNOLOGY LANDSCAPE

• 4.1. Chapter Overview
• 4.2. Long-Acting Drug Delivery: Technology Landscape
  • 4.2.1. Analysis by Principle
  • 4.2.2. Analysis by Strategy
  • 4.2.3. Analysis by Type of Material Used
  • 4.2.4. Analysis by Compatible Dosage Form(s)
  • 4.2.5. Analysis by Extended Dosing Interval(s)
  • 4.2.6. Analysis by Type of Molecule(s) Delivered
  • 4.2.7. Analysis by Highest Phase of Development
  • 4.2.8. Analysis by Number of Approved Drugs
  • 4.2.9. Analysis by Therapeutic Area(s)
• 4.3. Long-Acting Drug Delivery: Technology Developers Landscape
  • 4.3.1. Analysis by Year of Establishment
  • 4.3.2. Analysis by Company Size
  • 4.3.3. Analysis by Location of Headquarters
  • 4.3.4. Most Active Players: Analysis by Number of Technologies

5. SERVICE PROVIDERS LANDSCAPE

• 5.1. Chapter Overview
• 5.2. Long-Acting Drug Delivery: Service Providers Landscape
  • 5.2.1. Analysis by Year of Establishment
  • 5.2.2. Analysis by Company Size
  • 5.2.3. Analysis by Location of Headquarters
  • 5.2.4. Analysis by Company Size and Location of Headquarters
  • 5.2.5. Analysis by Location of Facilities
  • 5.2.6. Analysis by Type of Service Provider(s)
  • 5.2.7. Analysis by Scale of Operation
  • 5.2.8. Analysis by Compatible Dosage Form(s)
  • 5.2.9. Analysis by Scale of Operation and Compatible Dosage Form(s)
  • 5.2.10. Analysis by Service(s) Offered
  • 5.2.11. Analysis by Company Size and Service(s) Offered
  • 5.2.12. Analysis by Year of Establishment, Location of Headquarters and Service(s) Offered
  • 5.2.13. Analysis by Type of Molecule(s) Supported
  • 5.2.14. Analysis by Type of Service Provider(s) and Type of Molecule(s) Supported

6. TECHNOLOGY COMPETITIVENESS ANALYSIS

• 6.1. Chapter Overview
• 6.2. Assumptions / Key Parameters
• 6.3. Methodology
• 6.4. Technology Competitiveness Analysis
  • 6.4.1. Long-Acting Drug Delivery Technologies Offered by Small Companies
  • 6.4.2. Long-Acting Drug Delivery Technologies Offered by Mid-sized Companies
  • 6.4.3. Long-Acting Drug Delivery Technologies Offered by Large Companies
  • 6.4.4. Long-Acting Drug Delivery Technologies Offered by Very Large Companies

7. COMPANY COMPETITIVENESS ANALYSIS

• 7.1. Chapter Overview
• 7.2. Assumptions / Key Parameters
• 7.3. Methodology
• 7.4. Company Competitiveness Analysis
  • 7.4.1. Long-Acting Drug Delivery Service Providers based in North America
  • 7.4.2. Long-Acting Drug Delivery Service Providers based in Europe
  • 7.4.3. Long-Acting Drug Delivery Service Providers based in Asia-Pacific

8. COMPANY PROFILES

• 8.1. Chapter Overview
• 8.2. Adare Pharma Solutions
  • 8.2.1. Company Overview
  • 8.2.2. Technology Portfolio
  • 8.2.3. Service Portfolio
  • 8.2.4. Recent Developments and Future Outlook
• 8.3. AMW
  • 8.3.1. Company Overview
  • 8.3.2. Technology Portfolio
  • 8.3.3. Service Portfolio
  • 8.3.4. Recent Developments and Future Outlook
• 8.4. Bostal Drug Delivery
  • 8.4.1. Company Overview
  • 8.4.2. Technology Portfolio
  • 8.4.3. Service Portfolio
  • 8.4.4. Recent Developments and Future Outlook
• 8.5. Creative Biolabs
  • 8.5.1. Company Overview
  • 8.5.2. Technology Portfolio
  • 8.5.3. Service Portfolio
  • 8.5.4. Recent Developments and Future Outlook
• 8.6. ForDoz Pharma
  • 8.6.1. Company Overview
  • 8.6.2. Technology Portfolio
  • 8.6.3. Service Portfolio
  • 8.6.4. Recent Developments and Future Outlook
• 8.7. InnoCore Pharmaceuticals
  • 8.7.1. Company Overview
  • 8.7.2. Technology Portfolio
  • 8.7.3. Service Portfolio
  • 8.7.4. Recent Developments and Future Outlook
• 8.8. Integral BioSystems
  • 8.8.1. Company Overview
  • 8.8.2. Technology Portfolio
  • 8.8.3. Service Portfolio
  • 8.8.4. Recent Developments and Future Outlook
• 8.9. LATITUDE Pharmaceuticals
  • 8.9.1. Company Overview
  • 8.9.2. Technology Portfolio
  • 8.9.3. Service Portfolio
  • 8.9.4. Recent Developments and Future Outlook
• 8.10. Navin Saxena Research and Technology Centre (NSRT)
  • 8.10.1. Company Overview
  • 8.10.2. Technology Portfolio
  • 8.10.3. Service Portfolio
  • 8.10.4. Recent Developments and Future Outlook
• 8.11. Samyang Biopharm
  • 8.11.1. Company Overview
  • 8.11.2. Technology Portfolio
  • 8.11.3. Service Portfolio
  • 8.11.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS

• 9.1. Chapter Overview
• 9.2. Partnership Models
• 9.3. Long-Acting Drug Delivery Technologies and Services: Partnerships and Collaborations
  • 9.3.1. Analysis by Year of Partnership
  • 9.3.2. Analysis by Type of Partnership
  • 9.3.3. Analysis by Year and Type of Partnership
  • 9.3.4. Analysis by Type of Partner
  • 9.3.5. Analysis by Location of Headquarters of Partner
  • 9.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
  • 9.3.7. Most Active Players: Analysis by Number of Partnerships
  • 9.3.8. Analysis by Region
    • 9.3.8.1. Intercontinental and Intracontinental Deals
    • 9.3.8.2. Local and International Deals

10. PUBLICATION ANALYSIS

• 10.1. Chapter Overview
• 10.2. Scope and Methodology
• 10.3. Long-Acting Drug Delivery: Publication Analysis
  • 10.3.1. Analysis by Year of Publication
  • 10.3.2. Analysis by Type of Publication
  • 10.3.3. Analysis by Most Popular Keywords
  • 10.3.4. Most Popular Journals: Analysis by Number of Publications
  • 10.3.5. Most Popular Publishers: Analysis by Number of Publications
  • 10.3.6. Most Popular Copyright Holders: Analysis by Number of Publications
  • 10.3.7. Key Funding Institutes: Analysis by Number of Publications

11. PATENT ANALYSIS

• 11.1. Chapter Overview
• 11.2. Scope and Methodology
• 11.3. Long-Acting Drug Delivery: Patent Analysis
  • 11.3.1. Analysis by Publication Year
  • 11.3.2. Analysis by Type of Patent and Publication Year
  • 11.3.3. Analysis by Geography
  • 11.3.4. Analysis by CPC Symbols
  • 11.3.5. Leading Industry Players: Analysis by Number of Patents
  • 11.3.6. Analysis by Type of Organization
• 11.4. Patent Benchmark Analysis
  • 11.4.1. Analysis by Patent Characteristics
• 11.5. Patent Valuation Analysis

12. GRANT ANALYSIS

• 12.1. Chapter Overview
• 12.2. Scope and Methodology
• 12.3. Long-Acting Drug Delivery: Grant Analysis
  • 12.3.1. Analysis by Year of Grant Awarded
  • 12.3.2. Analysis by Amount Awarded
  • 12.3.3. Analysis by Support Period
  • 12.3.4. Analysis by Support Period and Funding Institute Center
  • 12.3.5. Analysis by Type of Grant Application
  • 12.3.6. Analysis by Purpose of Grant
  • 12.3.7. Analysis By Activity Code
  • 12.3.8. Analysis by NIH Spending Category
  • 12.3.9. Analysis by Study Section Involved
  • 12.3.10. Popular NIH Departments: Analysis by Number of Grants
  • 12.3.11. Analysis by Type of Recipient Organization
  • 12.3.12. Prominent Program Officers: Analysis by Number of Grants
  • 12.3.13. Popular Recipient Organizations: Analysis by Number of Grants
  • 12.3.14. Popular Recipient Organizations: Analysis by Grant Amount
  • 12.3.15. Analysis by Region of Recipient Organizations

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 13.1. Chapter Overview
• 13.2. Key Assumptions and Forecast Methodology
• 13.3. Global Long-Acting Drug Delivery Technologies Market, till 2035
  • 13.3.1. Long-Acting Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed
    • 13.3.1.1. Long-Acting Drug Delivery Technologies Market for Upfront Payment, till 2035
    • 13.3.1.2. Long-Acting Drug Delivery Technologies Market for Milestone Payment, till 2035
  • 13.3.2. Long-Acting Drug Delivery Technologies Market: Analysis by Principle
    • 13.3.2.1. Long-Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, till 2035
    • 13.3.2.2. Long-Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, till 2035
  • 13.3.3. Long-Acting Drug Delivery Technologies Market: Analysis by Strategy
    • 13.3.3.1. Long-Acting Drug Delivery Technologies Market for Micro-encapsulation, till 2035
    • 13.3.3.2. Long-Acting Drug Delivery Technologies Market for Long-Acting Implants, till 2035
    • 13.3.3.3. Long-Acting Drug Delivery Technologies Market for Multivesicular Liposomes, till 2035
    • 13.3.3.4. Long-Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, till 2035
    • 13.3.3.5. Long-Acting Drug Delivery Technologies Market for Long-Acting Hydrogels, till 2035
    • 13.3.3.6. Long-Acting Drug Delivery Technologies Market for Long-Acting Microneedles, till 2035
    • 13.3.3.7. Long-Acting Drug Delivery Technologies Market for Chemical Modification, till 2035
    • 13.3.3.8. Long-Acting Drug Delivery Technologies Market for Protein Fusion, till 2035
  • 13.3.4. Long-Acting Drug Delivery Technologies Market: Analysis by Compatible Dosage Form
    • 13.3.4.1. Long-Acting Drug Delivery Technologies Market for Injectables, till 2035
    • 13.3.4.2. Long-Acting Drug Delivery Technologies Market for Implantables, till 2035
    • 13.3.4.3. Long-Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, till 2035
    • 13.3.4.4. Long-Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, till 2035
    • 13.3.4.5. Long-Acting Drug Delivery Technologies Market for Oral Dosage Forms, till 2035
    • 13.3.4.6. Long-Acting Drug Delivery Technologies Market for Other Dosage Forms, till 2035
  • 13.3.5. Long-Acting Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered
    • 13.3.5.1. Long-Acting Drug Delivery Technologies Market for Small Molecules, till 2035
    • 13.3.5.2. Long-Acting Drug Delivery Technologies Market for Biologics, till 2035
    • 13.3.5.3. Long-Acting Drug Delivery Technologies Market for Other Molecules, till 2035
  • 13.3.6. Long-Acting Drug Delivery Technologies Market: Analysis by Type of Material Used
    • 13.3.6.1. Long-Acting Drug Delivery Technologies Market for Polymer-based Material, till 2035
    • 13.3.6.2. Long-Acting Drug Delivery Technologies Market for Non-polymer based Material, till 2035
  • 13.3.7. Long-Acting Drug Delivery Technologies Market: Analysis by Region
    • 13.3.7.1. Long-Acting Drug Delivery Technologies Market in North America, till 2035
    • 13.3.7.2. Long-Acting Drug Delivery Technologies Market in Europe, till 2035
    • 13.3.7.3. Long-Acting Drug Delivery Technologies Market in Asia-Pacific, till 2035
    • 13.3.7.4. Long-Acting Drug Delivery Technologies Market in Middle East and North Africa, till 2035
• 13.4. Global Long-Acting Drug Delivery Services Market, till 2035
  • 13.4.1. Long-Acting Drug Delivery Services Market: Analysis by Compatible Dosage Form
    • 13.4.1.1. Long-Acting Drug Delivery Services Market for Injectables, till 2035
    • 13.4.1.2. Long-Acting Drug Delivery Services Market for Implantables, till 2035
    • 13.4.1.3. Long-Acting Drug Delivery Services Market for Vaginal Dosage Forms, till 2035
    • 13.4.1.4. Long-Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, till 2035
    • 13.4.1.5. Long-Acting Drug Delivery Services Market for Oral Dosage Forms, till 2035
    • 13.4.1.6. Long-Acting Drug Delivery Services Market for Other Dosage Forms, till 2035
  • 13.4.2. Long-Acting Drug Delivery Services Market: Analysis by Type of Molecule Supported
    • 13.4.2.1. Long-Acting Drug Delivery Services Market for Small Molecules, till 2035
    • 13.4.2.2. Long-Acting Drug Delivery Services Market for Biologics, till 2035
    • 13.4.2.3. Long-Acting Drug Delivery Services Market for Other Molecules, till 2035
  • 13.4.3. Long-Acting Drug Delivery Services Market: Analysis by Region
    • 13.4.3.1. Long-Acting Drug Delivery Services Market in North America, till 2035
    • 13.4.3.2. Long-Acting Drug Delivery Services Market in Europe, till 2035
    • 13.4.3.3. Long-Acting Drug Delivery Services Market in Asia-Pacific, till 2035

14. CONCLUSION

15. INTERVIEW TRANSCRIPTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료